Harvard-MIT Center for Reg. Science Lecture (4-4-23) - Dubious FDA drug Approvals

VP goes to Denmark to give the keynote at the Danish medical association conference

5.47 - Real World Evidence - Keynote Lecture in Denmark

5.46 - What is Science: reflections on the field

Karmma  3 discussion; then Sensible Medicine on Long COVID, 4th year fellowships and more; Then my breakdown of FDA's NEJM Letter to the Editor

5.45 - Bar Karmma - Karmma 3 | Idacel vs 'standard care

I get into endpoints, surrogates, validation, blinding, crossover, and control arms.

More basics on randomized controlled trials - Part 2

Papa Heme

I talk RCTs 101; KM Plots; Blinding: 2:1 randomization: Concealment and more.  Then Papa Heme Tells you How to Find your First Job

RCT 101 And Papa Heme

Tom Newman

Dr. Tom Newman UCSF Emeritus Professor &amp; Superb teacher discusses VP's recent Public Health Videos. The two don't fully agree, but the discussion is worth your time.

Tom Newman And VP Discuss Public Health

Michael Putman

Mike Putman, asst prof. EBM Rhematologist debates me on value of boosters, observational studies and more.

5.41 - Michael Putman MCW debates me on recent policy Qs

A new podcast feed called Sensible Medicine is up; here is a sample of what we have to offer

Sensible Med Superbowl Plenary Session Crossover

I destroy the trial.  Bad control arm. Informative Censoring. No OS gain. Authors DOWNPOWERED TRIAL. Fishy PFS. Fishy HRQoL. This trial should be in trash can.

5.39 - Sotorasib and Codebreak 200

A podcast on medicine, oncology, &amp; health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco.Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

This is a great stream of critical appraisal of the literature.

For a practicing hematologist/oncologist, this should replace something else you are listening to.

A necessary voice at a critical time in health care, science, and society!

Must Listen

A podcast on medicine, oncology, &amp; health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Plenary Session

Bernard Fisher

Mark Lewis

This week we give a short monologue on the late Dr. Bernard Fisher's legacy in the field of oncology, and then dive into a far-ranging interview with Dr. Mark Lewis of Intermountain Healthcare on his career, his family, and diagnosing himself with MEN1 syndrome. Dr. Fisher's obituary in the New York Times: https://www.nytimes.com/2019/10/19/science/dr-bernard-fisher-dead.htmlBack us on Patreon! www.patreon.com/plenarysession

This week we give a short monologue on the late Dr. Bernard Fisher's legacy in the field of oncology, and then dive into a far-ranging interview with Dr. Mark Lewis of Intermountain Healthcare on his career, his family, and diagnosing himself with MEN1 syndrome. Dr. Fisher's obituary in the New York Times: <a href="https://www.nytimes.com/2019/10/19/science/dr-bernard-fisher-dead.html" rel="nofollow" target="_blank">https://www.nytimes.com/2019/10/19/science/dr-bernard-fisher-dead.html</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

2.19 Remembering Dr. Bernard Fisher & Self-Diagnosis with Dr. Mark Lewis

Andrae Vandross

We're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA approval for nivolumab in small-cell lung cancer. In the second half of the show, we'll interview Dr. Andrae Vandross, a community oncologist at UCLA Medical Center.

1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross

We're back in Plenary Session HQ! We have multiple topics for you this week. We cover the use of trastuzumab in later lines of therapy for HER2+ metastatic breast cancer, we take a listener question on Kaplan-Meier curves, and we talk a little about Patreon.Malignant: www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635Back us on Patreon! www.patreon.com/plenarysession

We're back in Plenary Session HQ! We have multiple topics for you this week. We cover the use of trastuzumab in later lines of therapy for HER2+ metastatic breast cancer, we take a listener question on Kaplan-Meier curves, and we talk a little about Patreon. Malignant: <a href="http://www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635" rel="nofollow" target="_blank">www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

2.28 Trastuzumab in Later Lines of Therapy for HER2+ Breast Cancer, Kaplan-Meier Curves, & Patreon

Adam Cifu

We start this week's episode with a Question of the Week from medical student Audrey Tran on translational research and medical student training. Afterwards, we have an in-depth interview with Dr. Adam Cifu of the University of Chicago on his recent publication: "Physical Examination Pet Peeves". Pet Peeves: doi.org/10.4300/JGME-D-18-01063.1Back us on Patreon! www.patreon.com/plenarysession

We start this week's episode with a Question of the Week from medical student Audrey Tran on translational research and medical student training. Afterwards, we have an in-depth interview with Dr. Adam Cifu of the University of Chicago on his recent publication: "Physical Examination Pet Peeves". Pet Peeves: <a href="http://doi.org/10.4300/JGME-D-18-01063.1" rel="nofollow" target="_blank">doi.org/10.4300/JGME-D-18-01063.1</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

2.07 Translational Research & Physical Examination Pet Peeves with Dr. Adam Cifu

Avi O'Glasser

This week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.

1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser

This BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. Backers of our Patreon will be sent accompanying slides.Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

1.30 BONUS! Clinical Trial Endpoints, Drug Approval, Incentives in Oncology

Stephen Bradley

Today we talk with Dr. Stephen Bradley, a General Practitioner and Clinical Research Fellow at the University of Leeds, on publishing in medical journals -- peer review, editorial practices, anti-intellectualism, and more!Notes on Nationalism: www.orwellfoundation.com/the-orwell-foundation/orwell/essays-and-other-works/notes-on-nationalism/Back us on Patreon! www.patreon.com/plenarysessionCheck out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Today we talk with Dr. Stephen Bradley, a General Practitioner and Clinical Research Fellow at the University of Leeds, on publishing in medical journals -- peer review, editorial practices, anti-intellectualism, and more! Notes on Nationalism: <a href="http://www.orwellfoundation.com/the-orwell-foundation/orwell/essays-and-other-works/notes-on-nationalism/" rel="nofollow" target="_blank">www.orwellfoundation.com/the-orwell-foundation/orwell/essays-and-other-works/notes-on-nationalism/</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a> Check out our YouTube channel: <a href="http://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew" rel="nofollow" target="_blank">www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew</a>

3.32 Publishing Original Thought in Medical Journals with Dr. Stephen Bradley

Sven Olson

In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices.Caplacizumab: doi.org/10.1056/NEJMoa1806311Back us on Patreon! www.patreon.com/plenarysession

In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices. Caplacizumab: <a href="http://doi.org/10.1056/NEJMoa1806311" rel="nofollow" target="_blank">doi.org/10.1056/NEJMoa1806311</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

1.42 Caplacizumab for TTP with Dr. Sven Olson & Economics of Drug Pricing with Dr. Inma Hernández

Ellie Murray

This week we return to our discussion of going after soft targets vs hard targets, but this time with a focus on how it applies to building a burgeoning career in medicine, in our segment Questions from a Medical Student with Audrey Tran. We end this week's episode with a far-reaching interview with Dr. Ellie Murray (most people know her as Epi Ellie on Twitter and as the co-host of the podcast Casual Inference) on all things epidemiology.Check out Dr. Murray's excellent podcast here: https://casualinfer.libsyn.com/Back us on Patreon! www.patreon.com/plenarysession

This week we return to our discussion of going after soft targets vs hard targets, but this time with a focus on how it applies to building a burgeoning career in medicine, in our segment Questions from a Medical Student with Audrey Tran. We end this week's episode with a far-reaching interview with Dr. Ellie Murray (most people know her as Epi Ellie on Twitter and as the co-host of the podcast Casual Inference) on all things epidemiology. Check out Dr. Murray's excellent podcast here: <a href="https://casualinfer.libsyn.com/" rel="nofollow" target="_blank">https://casualinfer.libsyn.com/</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

2.30 Questions from a Medical Student & Epidemiology with Dr. Ellie Murray

Tom Beer

In this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing.Back us on Patreon! www.patreon.com/plenarysession

In this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing. Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

1.46 BONUS! Personal Finances with Dr. Tom Beer

This BONUS episode is the recording of a talk given at the Salem City Club on January 11, 2019. It's the talk on medical reversal that has been featured in previous episodes, but this time the format and content have been updated for a broader, more general audience.Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is the recording of a talk given at the Salem City Club on January 11, 2019. It's the talk on medical reversal that has been featured in previous episodes, but this time the format and content have been updated for a broader, more general audience. Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

1.37 BONUS! Medical Reversal for a General Audience

This BONUS episode is the recording of a two-part talk addressed to oncology fellows given at Oregon Health &amp; Science University on October 5 and October 12, 2018. The talk is on how to interpret cancer clinical trials.

1.17 BONUS! Interpretation of Cancer Clinical Trials

Adewole Adamson

Benjamin Mazer

For today's episode, we sit down with Drs. Ade Adamson of the University of Texas at Austin Dell Medical School and Ben Mazer of Johns Hopkins Hospital to discuss their new paper out now in the New England Journal of Medicine titled "The Rapid Rise in Cutaneous Melanoma Diagnoses". It's one of the best papers you'll read all year.Melanoma Diagnoses: doi.org/10.1056/NEJMsb2019760Back us on Patreon! www.patreon.com/plenarysessionCheck out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

For today's episode, we sit down with Drs. Ade Adamson of the University of Texas at Austin Dell Medical School and Ben Mazer of Johns Hopkins Hospital to discuss their new paper out now in the New England Journal of Medicine titled "The Rapid Rise in Cutaneous Melanoma Diagnoses". It's one of the best papers you'll read all year. Melanoma Diagnoses: <a href="http://doi.org/10.1056/NEJMsb2019760" rel="nofollow" target="_blank">doi.org/10.1056/NEJMsb2019760</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a> Check out our YouTube channel: <a href="http://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew" rel="nofollow" target="_blank">www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew</a>

3.42 Overdiagnosis and Cutaneous Melanoma Diagnoses with Dr. Adewole Adamson and Dr. Benjamin Mazer

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-XRivaroxaban: doi.org/10.1056/NEJMoa1814630Apixaban: doi.org/10.1056/NEJMoa1814468Back us on Patreon! www.patreon.com/plenarysession

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: <a href="http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X" rel="nofollow" target="_blank">www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X</a> Rivaroxaban: <a href="http://doi.org/10.1056/NEJMoa1814630" rel="nofollow" target="_blank">doi.org/10.1056/NEJMoa1814630</a> Apixaban: <a href="http://doi.org/10.1056/NEJMoa1814468" rel="nofollow" target="_blank">doi.org/10.1056/NEJMoa1814468</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson

David Carr

This week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our thoughts on what they said. We then turn to the FDA's recent approval of neratinib in combination with capecitabine for HER2-positive breast cancer, based on the phase III NALA trial. Finally, we interview Dr. David Carr, a Molecular Pathology Fellow at UC San Diego, on his work in general and, specifically, next-generation sequencing.BEACON Letters to the Editor: www.nejm.org/doi/full/10.1056/NEJMoa1908075#article_lettersNALA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancerVinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635Back us on Patreon! www.patreon.com/plenarysession

This week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our thoughts on what they said. We then turn to the FDA's recent approval of neratinib in combination with capecitabine for HER2-positive breast cancer, based on the phase III NALA trial. Finally, we interview Dr. David Carr, a Molecular Pathology Fellow at UC San Diego, on his work in general and, specifically, next-generation sequencing. BEACON Letters to the Editor: <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1908075#article_letters" rel="nofollow" target="_blank">www.nejm.org/doi/full/10.1056/NEJMoa1908075#article_letters</a> NALA: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer" rel="nofollow" target="_blank">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer</a> Vinay's new book, Malignant: <a href="http://www.amazon.com/Malignant-Policy-…cer/dp/1421437635" rel="nofollow" target="_blank">www.amazon.com/Malignant-Policy-…cer/dp/1421437635</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

2.40 BEACON part 2, NALA, & Molecular Pathology and Next-Generation Sequencing with Dr. David Carr

On today's episode we sit down with Dr. Arye Elfenbein, a cardiologist and "doctorpreneur " to interview him on the bio-tech company he recently co-founded: Wildtype. Wildtype manufactures ex-vivo fish meat for human consumption in fulfillment of their mission to create the cleanest, most sustainable seafood.Back us on Patreon! www.patreon.com/plenarysessionCheck out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

On today's episode we sit down with Dr. Arye Elfenbein, a cardiologist and "doctorpreneur " to interview him on the bio-tech company he recently co-founded: Wildtype. Wildtype manufactures ex-vivo fish meat for human consumption in fulfillment of their mission to create the cleanest, most sustainable seafood. Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a> Check out our YouTube channel: <a href="http://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew" rel="nofollow" target="_blank">www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew</a>

3.36 Sustainable Ex-Vivo Seafood with Dr. Arye Elfenbein

Derrick Tao

Martha Gerrity

In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.

1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity

Adam Obley

In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate.Medical conferences: doi.org/10.1001/jama.2012.360

In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate. Medical conferences: <a href="http://doi.org/10.1001/jama.2012.360" rel="nofollow" target="_blank">doi.org/10.1001/jama.2012.360</a>

1.24 Useless Medical Conferences and Dr. Adam Obley on Vascepa, Fish Oil, Vitamin D and Methotrexate

Talal Hilal

Arjun Gupta

This week we discuss three paired papers on precision oncology published in Nature Medicine and then, later in the episode, go in-depth on the implications of these negative studies with Dr. Talal Hilal of the Mayo Clinic. We also discuss the use of magic mouthwash for oral mucositis with Plenary Session fan, Dr. Arjun Gupta of Johns Hopkins University. WINTHER: doi.org/10.1038/s41591-019-0424-4TARGET: doi.org/10.1038/s41591-019-0380-zI-PREDICT: doi.org/10.1038/s41591-019-0407-5Magic mouthwash: doi.org/10.1001/jamainternmed.2018.6223Back us on Patreon! www.patreon.com/plenarysession

This week we discuss three paired papers on precision oncology published in Nature Medicine and then, later in the episode, go in-depth on the implications of these negative studies with Dr. Talal Hilal of the Mayo Clinic. We also discuss the use of magic mouthwash for oral mucositis with Plenary Session fan, Dr. Arjun Gupta of Johns Hopkins University. WINTHER: <a href="http://doi.org/10.1038/s41591-019-0424-4" rel="nofollow" target="_blank">doi.org/10.1038/s41591-019-0424-4</a> TARGET: <a href="http://doi.org/10.1038/s41591-019-0380-z" rel="nofollow" target="_blank">doi.org/10.1038/s41591-019-0380-z</a> I-PREDICT: <a href="http://doi.org/10.1038/s41591-019-0407-5" rel="nofollow" target="_blank">doi.org/10.1038/s41591-019-0407-5</a> Magic mouthwash: <a href="http://doi.org/10.1001/jamainternmed.2018.6223" rel="nofollow" target="_blank">doi.org/10.1001/jamainternmed.2018.6223</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

1.58 Magic Mouthwash with Dr. Arjun Gupta & Precision Oncology with Dr. Talal Hilal

Our host is still out of town, but don't worry -- we have some questions of the week to tide you over. The first is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; the second is inspired by the USMLE Step 2 CK, presented by Ian Straehley; and the third is from Audrey Tran, inspired by her experiences as a med student.Back us on Patreon! www.patreon.com/plenarysession

Our host is still out of town, but don't worry -- we have some questions of the week to tide you over. The first is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; the second is inspired by the USMLE Step 2 CK, presented by Ian Straehley; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

2.25 Questions of the Week: Hematology/Oncology, the USMLE Step 2 CK, & One From a Med Student

The best podcast episodes about true crime. For any thrill seeking podcast listeners who just can't get enough of the captivating stories of murderers and criminals. This topic has all the best episodes from many different true crime podcasts.  Add episodes you're interested into your queue below!

Best True Crime Podcasts

The best podcast episodes on global issues affecting everyone. Covering topics such as the #metoo movement, climate change, the impact of technology and some of the biggest global issues facing us right now. For anyone interested in learning more about the world, and some of the issues we're facing, pick an episode below and start listening! Add episodes you're interested into your queue below!